← all works
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Diabetes Treatment and Management
- Field
- Medicine
- Canadian institutions
- University of TorontoSt. Michael's Hospital
- Funders
- National Institutes of HealthSirtex MedicalServierNovo NordiskBoston Scientific CorporationBristol-Myers SquibbEli Lilly and CompanyAstraZenecaCSL BehringGilead SciencesGlaxoSmithKlineAmgenPfizerDaiichi Sankyo EuropeSanofiAbbott Laboratories
- Keywords
- MedicinePlaceboType 2 diabetesDouble blindDiseaseInternal medicineDiabetes mellitusPhysical therapyAlternative medicineEndocrinology
- Has abstract in OpenAlex
- no